Antiviral Development for the Polio Endgame: Current Progress and Future Directions.

Area of Science:

• Virology
• Immunology
• Drug Discovery

Background:

• Global efforts are nearing wild poliovirus serotype 1 eradication.
• Oral polio vaccines (OPVs) carry a risk of vaccine-associated paralytic polio (VAPP).
• Immunodeficiency-associated vaccine-derived poliovirus (iVDPV) poses a threat in B cell-deficient individuals.

Purpose of the Study:

• To review progress in developing safe and effective poliovirus antiviral drugs.
• To highlight promising antiviral candidates for treating iVDPV infections.
• To support the goal of a sustained polio-free world.

Main Methods:

• Literature review of poliovirus antiviral research.
• Summary of in vitro, in vivo, and clinical trial data.
• Analysis of drug candidates targeting poliovirus replication.

Main Results:

• Significant advancements in poliovirus antiviral drug discovery.
• Identification of several promising antiviral candidates.
• Demonstrated efficacy of certain antivirals in preclinical and clinical studies.

Conclusions:

• Antiviral drug development is essential for eradicating poliovirus and preventing VAPP.
• The Polio Antivirals Initiative (PAI) is key to addressing iVDPV risks.
• Continued research and clinical trials are needed to bring effective poliovirus antivirals to fruition.